COMPARE THE HUMAN PROOF
How the Proof Differs Across Five Compounds
Three have an FDA-approved use. One is still in late tests. One relies mostly on animals. Those gaps affect your questions.
Which compounds have the strongest human proof
Large human studies support the approved uses of semaglutide and tirzepatide. Tesamorelin has one approved use for an uncommon fat problem linked to HIV. Retatrutide is still in Phase 3 and lacks approval. BPC-157 depends mainly on animal findings and a few tiny human tests.
The table tells you what changed, who took part, and which harm needs care. It also lists FDA and sports rules. I’d start with your main health concern. Then ask how well you match the people in that row and what their result may mean for your care. You’ll see at once where human proof grows thin.
What changed and the chief warning for each
Phase 2 comes early. Phase 3 comes later.
| Compound | What it copies or affects | What studies checked | Human proof | FDA status | sports rule | Key warning |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1, a gut hormone for hunger and blood sugar | Weight, diabetes, heart and kidney disease | late studies, up to 17,604 people | Several approved uses | Not banned | Stomach trouble; eye risk when blood sugar falls fast [5][7] |
| Tirzepatide | GLP-1 and another gut hormone | Weight and diabetes | Phase 3 studies, up to 2,539 people | Approved for diabetes, obesity, and sleep apnea | Not banned | Stomach trouble; gallbladder or bile-duct trouble [9][10] |
| Tesamorelin | Your body’s call to release growth hormone | HIV fat changes, deep belly fat, and liver fat | Phase 3 studies in adults with HIV | Approved only for HIV lipodystrophy, a rare fat change | Banned during and outside events | Other uses aren’t proved; fat around the organs comes back once care ends [12][16] |
| Retatrutide | Two gut hormones plus glucagon | Weight, diabetes, and liver fat | Earlier human test done; Phase 3 still running | Not approved as of 2026 | Not now banned | Faster pulse; products sold outside studies can’t be checked [17][20] |
| BPC-157 | steps involved in tissue repair | Tissue repair, new blood flow, and the gut | Animal work; 3 tiny human tests | Not approved | Banned at all times | Much work came from one lab; only 3 human tests [22][23] |
Ask your doctor to explain the row linked to your health concern.
How each compound may affect your body
Semaglutide follows GLP-1, a gut hormone that helps your pancreas release insulin when blood sugar rises. GLP-1 also slows your stomach and eases hunger [6]. Tirzepatide follows GLP-1 and a second gut hormone. In one study, the two actions cut blood sugar and weight more than semaglutide did [11].
Tesamorelin tells the growth gland under your brain to release growth hormone. The liver responds by making IGF-1, a growth protein that helps break down fat around the organs [15]. Tesamorelin isn’t growth hormone itself.
Retatrutide follows GLP-1, that second gut hormone, and glucagon. Glucagon may help the body draw on stored fuel, which could add to weight loss seen in Phase 2 [17][18]. BPC-157 works differently. Animal tests link it with new blood flow and tissue repair [25]. No study has proved that healing in people. You can ask which human test matches your problem. That’s the question to keep beside your concern.
How many people joined and what changed
Semaglutide has the largest human tests listed here. One enrolled 17,604 adults with heart disease and excess weight. Their joined risk of heart death, heart attack, or stroke fell by 20% [3]. Another included 3,533 people with type 2 diabetes and kidney disease. Their main kidney risk fell by 24% [2].
Tirzepatide also has large Phase 2 and 3 studies. SURMOUNT-1 followed 2,539 adults, and the 15 mg group lost the most weight [10]. SURPASS-2 compared it with semaglutide in 1,879 people who had type 2 diabetes [11]. SURMOUNT-5 included 751 adults and found greater weight loss with tirzepatide [1].
Tesamorelin studies centered on adults with HIV. In one study, deep belly fat was still 18% lower through a 52-week study. Another study of 50 people found less belly and liver fat [14][16].
A Phase 2 retatrutide test had 338 adults. The 12 mg group lost far more than the placebo group [20]. A separate Phase 2 test followed 281 people with type 2 diabetes for 36 weeks [21]. Phase 3 findings aren’t ready.
BPC-157 has very little human work. It needs much larger tests in people. A 2025 review found just three small BPC-157 tests and no large, strong study [23]. A separate 2025 safety test gave BPC-157 through a vein to two healthy adults [22]. Ask whether the people studied shared your health. If they didn’t, ask how that limits the answer.
How approval and sports rules affect your choice
Semaglutide and tirzepatide have FDA approval for several health needs. The group that writes drug rules for tested sports doesn’t now ban either medicine. Athletes still need current rules.
Tesamorelin is approved only for lipodystrophy, an uncommon fat shift linked to HIV. No other use has approval. The sports group bans it during and outside events.
Retatrutide still lacked approval everywhere in mid-2026. Human testing isn’t finished. Products sold outside proper studies can’t be checked for contents or cleanliness.
BPC-157 has no approval. In 2023, the FDA said regular pharmacies can’t mix it for patients while safety concerns remain. Sports rules ban it at all times. Ask which rule touches you and how approval affects your care. You can ask how each rule changes your options.
Which warning matters for each compound
Stomach trouble is the main reason people stop semaglutide. SUSTAIN-6 also found more eye trouble when blood sugar fell fast in people with prior diabetic eye disease [7]. Much of the lost weight may return after stopping [4].
Stomach trouble is common with tirzepatide too. One review found more gallbladder or bile-duct trouble when those problems were joined [9].
Tesamorelin’s narrow approval matters. Adults with HIV lipodystrophy lost some fat from around their organs, which doesn’t prove the same benefit for others. That fat came back soon after care ended [16].
Retatrutide’s first warning is its lack of approval. In Phase 2, a faster pulse peaked near 24 weeks [20]. Long-term heart results remain unknown, and products from outside studies can’t be checked.
Most BPC-157 repair findings came from one group studying rats. Only three small human tests exist, and long-term human risk is unknown [23]. Ask your doctor which warning bears most on your care. Write down the answer beside each choice you discuss. You won’t need to remember every warning at once.